Women diagnosed with a rare and hard-to-treat form of ovarian cancer are now being offered new hope through innovative drugs. A recent successful clinical trial has shown promising results for women with low-grade serous ovarian cancer, a type of cancer that is notoriously resistant to traditional chemotherapy treatments.
The trial revealed that nearly one-third (31 per cent) of women with low-grade serous ovarian cancer experienced shrinkage or cessation of tumour growth when treated with a combination of avutometinib and defactinib. These drugs function by inhibiting signals that promote the growth of cancer cells. Particularly encouraging results were observed in patients with a KRAS gene mutation, with 44 per cent experiencing tumour shrinkage.
Experts are enthusiastic about the implications of these findings, as they anticipate that this new treatment approach could revolutionise global practices for treating this type of cancer. This development offers a ray of hope for women who have limited or no effective treatment options available to them.
Low-grade serous ovarian cancer primarily affects younger women and is known for its poor response to conventional chemotherapy. Diagnosis often occurs after the cancer has already spread, and more than 70 per cent of cases experience recurrence even after standard treatments have been administered.
Professor Susana Banerjee, a leading consultant medical oncologist involved in the trials at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research in London, emphasised the significance of the results. She highlighted the reduced side effects and toxicities associated with the drug combination compared to conventional treatments, suggesting a potentially improved quality of life for patients.
The development of these groundbreaking drugs is spearheaded by the biotech company Verastem Oncology. The study results, shared with the PA news agency, were presented at the International Gynaecologic Cancer Society’s meeting in Dublin. Among the 115 participants with low-grade serous ovarian cancer, 31 per cent exhibited tumour shrinkage or halted growth on the new drugs, far surpassing the response rates seen with chemotherapy or hormone therapies.
As the clinical trials progress, experts are now seeking to recruit patients for the upcoming phase three trial, with hopes of further enhancing the outcomes for individuals battling low-grade serous ovarian cancer. The promising advancements in treatment offer a glimmer of optimism for patients facing this challenging and often overlooked form of cancer.